Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable N salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting TYK2, and/or function of IL-12, IL-23 and/or INF-alpha, and/or in treating various associated diseases or disorders.

Abstract: Embodiments of the present invention relate to the field of communications methods and technologies, and in particular, to a transmission method and apparatus. The transmission method includes: generating, by a first device, a sequence based on one or more transmission parameters, where the one or more transmission parameters include at least one of the following: a time domain resource type, transmission waveform indication information, subcarrier spacing indication information, device type information, service type indication information, multiple-input multiple-output MIMO parameter information, duplex mode indication information, control channel format indication information, and transmission carrier indication information; generating to-be-transmitted information by using the sequence; and sending the to-be-transmitted information. According to the transmission method and apparatus in the embodiments of the present invention, a new transmission error check mechanism is provided.

Abstract: Disclosed are a thermoforming device and method for a flexible printed circuit board. The thermoforming device may include: a first forming mechanism provided with a first forming portion, the first forming portion being configured to carry the flexible printed circuit board to be processed; a second forming mechanism provided with a second forming portion which matches with the first forming portion, at least one of the first forming portion or the second forming portion is provided with a corresponding heating module configured for heat treatment of the flexible printed circuit board; a first driving mechanism configured to drive the first forming mechanism and the second forming mechanism to be displaced relative to each other in a first direction; a second driving mechanism configured to drive the second forming mechanism and the first forming mechanism to be displaced relative to each other in a second direction perpendicular to the first direction; and a controller.

Abstract: An audio visual haptic signal reconstruction method includes first utilizing a large-scale audio-visual database stored in a central cloud to learn knowledge, and transferring same to an edge node; then combining, by means of the edge node, a received audio-visual signal with knowledge in the central cloud, and fully mining semantic correlation and consistency between modals; and finally fusing the semantic features of the obtained audio and video signals and inputting the semantic features to a haptic generation network, thereby realizing the reconstruction of the haptic signal. The method effectively solves the problems that the number of audio and video signals of a multi-modal dataset is insufficient, and semantic tags cannot be added to all the audio-visual signals in a training dataset by means of manual annotation. Also, the semantic association between heterogeneous data of different modals are better mined, and the heterogeneity gap between modals are eliminated.

Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (A), Formula (II), Formula (III), Formula (IV), or Formula (V), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRASG12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer (e.g., non-small cell lung cancer) or endometrial cancer.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRASG12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer or endometrial cancer.

Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.

Abstract: Methods for training statistical models for modeling phononic energy and/or frequency dispersion, as well as phononic stability of materials as a function of an applied strain, as well as uses of these trained statistical models for elastic strain engineering of materials, are described.

Abstract: Compositions and methods related to multiaxially straining defect doped materials as well as their use in electrical circuits are generally described.

Abstract: Provided herein are novel C-terminal Srk Kinase (CSK) inhibitors, e.g., having Formula G, I, II, or III. Also provided are methods of preparing the novel CSK inhibitors and method of using the novel CSK inhibitors for treating diseases or disorder such as cancer or for promoting immune response in a subject in need thereof.

Abstract: Compositions and methods related to straining defect doped materials as well as their methods of use in electrical circuits are generally described.

Abstract: Methods for training statistical models for the bandgap and energy dispersion of materials as a function of an applied strain, as well as uses of these trained statistical models for elastic strain engineering of materials, are described.

Abstract: Provided herein are novel thyroid hormone receptor (TR) agonists e.g., having Formula I, II, or III. Also provided are methods of preparing the novel TR agonists and method of using the novel TR agonists for treating diseases or disorder modulated by TR agonists, such as NAFLD, NASH, diabetes, hyperlipidemia and/or hypercholesterolemia.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).

Abstract: Compositions and methods related to straining defect doped materials as well as their methods of use in electrical circuits are generally described.

Abstract: Improving execution of application program instructions by sending a READ cache memory request for an address from a processor to a cache memory controller, receiving a cache miss result for the address in response to the READ request, sending a READ memory directly request for the same address and then receiving the address's contents.

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).

Abstract: Compositions and methods related to straining defect doped materials as well as their methods of use in electrical circuits are generally described.

Abstract: Method, display panel, computer program product, and color shift correction apparatus include correcting a color shift of a self-luminescent display panel in which a current brightness level of at least one monochromatic luminescent device is obtained and a brightness attenuation level of the at least one monochromatic luminescent device is calculated. The brightness of the at least one monochromatic luminescent device is then compensated based on the current brightness level and the brightness attenuation level. The calculation of the brightness attenuation level is based on a recorded accumulated working time, and a pre-configured attenuation rate function of the at least one monochromatic luminescent device.